Comparative long-term follow-up study of persistence of immunity after JVC-001 measles, mumps, and rubella vaccination in Japanese children.

ABSTRACT: JVC-001 is a novel measles-mumps-rubella (MMR) combined vaccine. In the J301 clinical trial, healthy 1-y-old Japanese children received either JVC-001 or marketed measles-rubella (MR) and mumps vaccines as control group. Our aim was to compare the long-term results between these two groups. From the 861 participants in the J301 study, 502 were followed for approximately 4 y. Antibody titers were measured using measles neutralizing test (NT), rubella hemagglutination inhibition (HI), mumps plaque reduction NT (PRNT) against genotype D and NT against genotype G in total of 446 participants (216 in the JVC-001 group, 230 in the control group). No participants in either group were identified as having measles, rubella, or mumps during the study period. Seropositive rates of measles NT, rubella

SUBMITTER: Nakayama T 

PROVIDER: S-EPMC12645854 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature